Sequencing Endocrine and Targeted Therapies After CDK4/6 Inhibitor in ESR1-Mutant Breast Cancer Progression

In this segment, Drs. Mouabbi and Bardia turn their attention to one of the most challenging aspects of managing ER-positive, HER2-negative metastatic breast cancer: selecting and sequencing therapies after progression on first-line AI plus CDK4/6 inhibitor treatment. Dr. Bardia outlines a structured approach to second-line decision-making that begins with evaluating how long the patient benefited from initial therapy. Patients with prolonged disease control, often two years or longer, are more likely to retain endocrine sensitivity, which strongly influences subsequent treatment choices.

Next, the discussion emphasizes the importance of plasma-based genotyping to identify actionable mutations, particularly ESR1 and alterations in the PI3K/AKT/mTOR pathway, including PIK3CA, AKT1, and PTEN loss. These mutations frequently co-occur, creating complex therapeutic decisions. Disease burden and distribution, such as bone-only versus visceral involvement, are also considered, although both speakers stress that endocrine responsiveness often matters more than disease extent.

Using a hypothetical patient with both ESR1 and PIK3CA mutations, Dr. Bardia explains his preference for sequencing therapies based on efficacy and tolerability. Although targeted combinations such as fulvestrant plus alpelisib or capivasertib are effective, they carry higher toxicity. Subgroup analyses from EMERALD and EMBER-3 demonstrate that single-agent oral SERDs, such as elacestrant or imlunestrant, retain meaningful activity even in patients with dual mutations, particularly when prior CDK4/6 inhibitor benefit exceeded 12 months. As a result, starting with an oral SERD often provides durable benefit with a more favorable safety profile, reserving combination regimens for later lines.

Dr. Mouabbi reinforces this rationale by distinguishing ESR1 as an acquired resistance mutation and PIK3CA as a truncal alteration, supporting initial ER-directed therapy when disease tempo allows. The segment concludes with a nuanced discussion of patient selection, highlighting that single-agent endocrine therapy remains appropriate for many patients, including those with visceral disease, while combinations may be favored for patients with symptomatic or rapidly progressive disease.